Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 6/2020

26.02.2020 | Original Article

Myeloid-derived suppressor cells impede T cell functionality and promote Th17 differentiation in oral squamous cell carcinoma

verfasst von: Asif A. Dar, Rushikesh S. Patil, Trupti N. Pradhan, Devendra A. Chaukar, Anil K. D’Cruz, Shubhada V. Chiplunkar

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Oral tumor microenvironment is characterized by chronic inflammation signified with infiltrating leukocytes and soluble mediators which cause immune suppression. However, how immunosuppressive cells like myeloid-derived suppressor cells (MDSCs) maintain the immunosuppressive tumor microenvironment and influence T cell function in oral squamous cell carcinoma (OSCC) patients remains poorly understood. In the present study, we found that percentages of MDSCs were higher in oral cancer patients compared to healthy individuals and correlated with cancer stage. Monocytic MDSCs (M-MDSCs) were prevalent in the periphery, while granulocytic/polymorphonuclear subset dominated the tumor compartment. M-MDSCs suppressed the lymphocyte proliferation and decreased the CD3-ζ (zeta) chain expression and interferon gamma production. The percentage of M-MDSCs in peripheral blood correlated inversely with CD3-ζ chain expression in T cells of these patients. Interleukin 6 (IL-6)-induced phosphorylated STAT3-regulated programmed cell death ligand 1, CCAAT/enhancer-binding proteins alpha and beta and Interleukin 10 expression in MDSCs. MDSCs inhibited TGF-β-driven generation of induced regulatory T cells in vitro. M-MDSCs secreted interleukins IL-6, IL-1β, IL-23 and PGE2 and facilitated T-helper 17 (Th17) cell differentiation which utilizes nitric oxide synthase and cyclooxygenase 2 enzyme activity. Interestingly, OSCC patients showed increased levels of Th17 cells in peripheral blood and tumor tissue. Thus, increased frequency of MDSCs, Th17 cells and decreased expression of CD3-ζ chain portray T cell tolerance and chronic inflammatory state facilitating tumor growth.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Dar AA, D’Cruz A, Chaukar D, Chiplunkar S (2016) Targeting myeloid-derived suppressor cells (MDSCs) to rejuvenate the antitumor immunity in oral cancer. In: 2016 European journal of cancer: a conference of new ideas in cancer—challenging dogmas, pp S1–S72 Dar AA, D’Cruz A, Chaukar D, Chiplunkar S (2016) Targeting myeloid-derived suppressor cells (MDSCs) to rejuvenate the antitumor immunity in oral cancer. In: 2016 European journal of cancer: a conference of new ideas in cancer—challenging dogmas, pp S1–S72
2.
Zurück zum Zitat Dikshit R et al (2012) Cancer mortality in India: a nationally representative survey. Lancet 379(9828):1807–1816PubMedCrossRef Dikshit R et al (2012) Cancer mortality in India: a nationally representative survey. Lancet 379(9828):1807–1816PubMedCrossRef
3.
Zurück zum Zitat Pathak KA et al (2005) Advanced squamous cell carcinoma of lower gingivobuccal complex: patterns of spread and failure. Head Neck 27(7):597–602PubMedCrossRef Pathak KA et al (2005) Advanced squamous cell carcinoma of lower gingivobuccal complex: patterns of spread and failure. Head Neck 27(7):597–602PubMedCrossRef
4.
Zurück zum Zitat Feller L, Altini M, Lemmer J (2013) Inflammation in the context of oral cancer. Oral Oncol 49(9):887–892PubMedCrossRef Feller L, Altini M, Lemmer J (2013) Inflammation in the context of oral cancer. Oral Oncol 49(9):887–892PubMedCrossRef
5.
Zurück zum Zitat Dar AA et al (2016) Extracellular 2′,5′-oligoadenylate synthetase 2 mediates T-cell receptor CD3-zeta chain down-regulation via caspase-3 activation in oral cancer. Immunology 147(2):251–264PubMedCrossRef Dar AA et al (2016) Extracellular 2′,5′-oligoadenylate synthetase 2 mediates T-cell receptor CD3-zeta chain down-regulation via caspase-3 activation in oral cancer. Immunology 147(2):251–264PubMedCrossRef
6.
7.
Zurück zum Zitat Marvel D, Gabrilovich DI (2015) Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 125(9):3356–3364PubMedPubMedCentralCrossRef Marvel D, Gabrilovich DI (2015) Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 125(9):3356–3364PubMedPubMedCentralCrossRef
8.
10.
Zurück zum Zitat Pan PY et al (2010) Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 70(1):99–108PubMedCrossRef Pan PY et al (2010) Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 70(1):99–108PubMedCrossRef
11.
Zurück zum Zitat Lee MH et al (2018) Interleukin 17 and peripheral IL-17-expressing T cells are negatively correlated with the overall survival of head and neck cancer patients. Oncotarget 9(11):9825–9837PubMedPubMedCentralCrossRef Lee MH et al (2018) Interleukin 17 and peripheral IL-17-expressing T cells are negatively correlated with the overall survival of head and neck cancer patients. Oncotarget 9(11):9825–9837PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat He D et al (2010) IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 184(5):2281–2288PubMedPubMedCentralCrossRef He D et al (2010) IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 184(5):2281–2288PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Chung AS et al (2013) An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 19(9):1114–1123PubMedCrossRef Chung AS et al (2013) An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 19(9):1114–1123PubMedCrossRef
14.
Zurück zum Zitat Umansky V et al (2016) The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines (Basel) 4(4):36CrossRef Umansky V et al (2016) The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines (Basel) 4(4):36CrossRef
15.
Zurück zum Zitat Obermajer N et al (2013) Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J Exp Med 210(7):1433–1445PubMedPubMedCentralCrossRef Obermajer N et al (2013) Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J Exp Med 210(7):1433–1445PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Obermajer N et al (2011) Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118(20):5498–5505PubMedPubMedCentralCrossRef Obermajer N et al (2011) Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118(20):5498–5505PubMedPubMedCentralCrossRef
17.
18.
Zurück zum Zitat Groth, C., et al., Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer, 2018 Groth, C., et al., Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer, 2018
19.
Zurück zum Zitat Sade-Feldman M et al (2016) Clinical significance of circulating CD33+ CD11b+ HLA-DR− myeloid cells in stage-IV melanoma patients treated with ipilimumab. Clin Cancer Res 22:5661–5672PubMedCrossRef Sade-Feldman M et al (2016) Clinical significance of circulating CD33+ CD11b+ HLA-DR− myeloid cells in stage-IV melanoma patients treated with ipilimumab. Clin Cancer Res 22:5661–5672PubMedCrossRef
20.
Zurück zum Zitat Zhang B et al (2013) Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS ONE 8(2):e57114PubMedPubMedCentralCrossRef Zhang B et al (2013) Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS ONE 8(2):e57114PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Vasquez-Dunddel D et al (2013) STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 123(4):1580–1589PubMedPubMedCentralCrossRef Vasquez-Dunddel D et al (2013) STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 123(4):1580–1589PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Hermouet S, Bigot-Corbel E, Gardie B (2015) Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation. Mediat Inflamm 2015:145293 Hermouet S, Bigot-Corbel E, Gardie B (2015) Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation. Mediat Inflamm 2015:145293
23.
Zurück zum Zitat Chikamatsu K et al (2012) Immunosuppressive activity of CD14+ HLA-DR− cells in squamous cell carcinoma of the head and neck. Cancer Sci 103(6):976–983PubMedCrossRef Chikamatsu K et al (2012) Immunosuppressive activity of CD14+ HLA-DR− cells in squamous cell carcinoma of the head and neck. Cancer Sci 103(6):976–983PubMedCrossRef
24.
Zurück zum Zitat Chen WC et al (2017) Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck. Head Neck 39(2):347–355PubMedCrossRef Chen WC et al (2017) Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck. Head Neck 39(2):347–355PubMedCrossRef
25.
Zurück zum Zitat Corzo CA et al (2010) HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207(11):2439–2453PubMedPubMedCentralCrossRef Corzo CA et al (2010) HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207(11):2439–2453PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Eruslanov E et al (2012) Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 130(5):1109–1119PubMedCrossRef Eruslanov E et al (2012) Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 130(5):1109–1119PubMedCrossRef
27.
Zurück zum Zitat Christiansson L et al (2013) Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS ONE 8(1):e55818PubMedPubMedCentralCrossRef Christiansson L et al (2013) Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS ONE 8(1):e55818PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Jitschin R et al (2014) CLL-cells induce IDOhi CD14+ HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 124(5):750–760PubMedCrossRef Jitschin R et al (2014) CLL-cells induce IDOhi CD14+ HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 124(5):750–760PubMedCrossRef
29.
Zurück zum Zitat Gabrilovich DI et al (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166(9):5398–5406PubMedCrossRef Gabrilovich DI et al (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166(9):5398–5406PubMedCrossRef
30.
Zurück zum Zitat Lechner MG, Liebertz DJ, Epstein AL (2010) Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 185(4):2273–2284PubMedPubMedCentralCrossRef Lechner MG, Liebertz DJ, Epstein AL (2010) Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 185(4):2273–2284PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Bu LL et al (2016) Targeting STAT3 signaling reduces immunosuppressive myeloid cells in head and neck squamous cell carcinoma. Oncoimmunology 5(5):e1130206PubMedPubMedCentralCrossRef Bu LL et al (2016) Targeting STAT3 signaling reduces immunosuppressive myeloid cells in head and neck squamous cell carcinoma. Oncoimmunology 5(5):e1130206PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Hsu P et al (2015) IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1. J Immunol 195(8):3665–3674PubMedCrossRef Hsu P et al (2015) IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1. J Immunol 195(8):3665–3674PubMedCrossRef
33.
Zurück zum Zitat Hoechst B et al (2008) A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135(1):234–243PubMedCrossRef Hoechst B et al (2008) A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135(1):234–243PubMedCrossRef
34.
Zurück zum Zitat Schouppe E et al (2013) Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur J Immunol 43(11):2930–2942PubMedCrossRef Schouppe E et al (2013) Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur J Immunol 43(11):2930–2942PubMedCrossRef
35.
Zurück zum Zitat Centuori SM et al (2012) Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-beta-induced differentiation of CD4+ CD25+ FoxP3+ Tregs from CD4+ CD25-FoxP3− T cells. J Leukoc Biol 92(5):987–997PubMedPubMedCentralCrossRef Centuori SM et al (2012) Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-beta-induced differentiation of CD4+ CD25+ FoxP3+ Tregs from CD4+ CD25-FoxP3− T cells. J Leukoc Biol 92(5):987–997PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Basu R et al (2015) IL-1 signaling modulates activation of STAT transcription factors to antagonize retinoic acid signaling and control the TH17 cell-iTreg cell balance. Nat Immunol 16(3):286–295PubMedPubMedCentralCrossRef Basu R et al (2015) IL-1 signaling modulates activation of STAT transcription factors to antagonize retinoic acid signaling and control the TH17 cell-iTreg cell balance. Nat Immunol 16(3):286–295PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Bruchard M et al (2013) Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19(1):57–64PubMedCrossRef Bruchard M et al (2013) Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19(1):57–64PubMedCrossRef
38.
Zurück zum Zitat Wu H et al (2016) Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus. Sci Transl Med 8(331):331ra40PubMedPubMedCentralCrossRef Wu H et al (2016) Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus. Sci Transl Med 8(331):331ra40PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Guo C et al (2016) Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. Ann Rheum Dis 75(1):278–285PubMedCrossRef Guo C et al (2016) Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis. Ann Rheum Dis 75(1):278–285PubMedCrossRef
40.
41.
Zurück zum Zitat Holmgaard RB et al (2016) Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine 6:50–58PubMedPubMedCentralCrossRef Holmgaard RB et al (2016) Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine 6:50–58PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Holmgaard RB et al (2016) Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. Oncoimmunology 5(7):e1151595PubMedPubMedCentralCrossRef Holmgaard RB et al (2016) Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. Oncoimmunology 5(7):e1151595PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Davis RJ et al (2017) Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid-derived suppressor cells with a selective inhibitor of PI3Kdelta/gamma. Cancer Res 77(10):2607–2619PubMedPubMedCentralCrossRef Davis RJ et al (2017) Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid-derived suppressor cells with a selective inhibitor of PI3Kdelta/gamma. Cancer Res 77(10):2607–2619PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Weed DT et al (2015) Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 21(1):39–48PubMedCrossRef Weed DT et al (2015) Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 21(1):39–48PubMedCrossRef
46.
Zurück zum Zitat Fultang L et al (2019) MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. EBioMedicine 47:235–246PubMedPubMedCentralCrossRef Fultang L et al (2019) MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. EBioMedicine 47:235–246PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Ishii H et al (2018) Establishment of synergistic chemoimmunotherapy for head and neck cancer using peritumoral immature dendritic cell injections and low-dose chemotherapies. Transl Oncol 11(1):132–139PubMedCrossRef Ishii H et al (2018) Establishment of synergistic chemoimmunotherapy for head and neck cancer using peritumoral immature dendritic cell injections and low-dose chemotherapies. Transl Oncol 11(1):132–139PubMedCrossRef
48.
Zurück zum Zitat Bruger AM, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T, Santibanez J, Saraiva M, Van Ginderachter JA, Brandau S (2019) How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother 68(4):631–644PubMedCrossRef Bruger AM, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T, Santibanez J, Saraiva M, Van Ginderachter JA, Brandau S (2019) How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother 68(4):631–644PubMedCrossRef
Metadaten
Titel
Myeloid-derived suppressor cells impede T cell functionality and promote Th17 differentiation in oral squamous cell carcinoma
verfasst von
Asif A. Dar
Rushikesh S. Patil
Trupti N. Pradhan
Devendra A. Chaukar
Anil K. D’Cruz
Shubhada V. Chiplunkar
Publikationsdatum
26.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 6/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02523-w

Weitere Artikel der Ausgabe 6/2020

Cancer Immunology, Immunotherapy 6/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.